Genor Biopharma Co., Ltd.

Changzhou Bojia Biotechnology Co., Ltd

Mab-venture Biopharm Co., Ltd.

Mab-legend Biotech Co., Ltd.

Shaoxiong Wang

Juehua Xu

Jun Wang

Ming Hsi Wang

Jing Zhao

Jun Lin

Fei Song

Joe Zhou

Jianyang Zhao

Jiuru Sun

John L Xu

Yunhua Zhou

Xinxing Ma

Yongfeng Chen

Provided in the present application are an antibody against factor XIa in the activated form of coagulant factor XI, a preparation method therefor and the use thereof. The CDR of the heavy chain variable region of the antigen-binding fragment of the antibody comprises the amino acid sequence shown in SEQ ID NOs: 1-3, and the CDR of the light chain variable region thereof comprises the amino acid sequence shown in SEQ ID NOs: 4-6. The antibody can specifically bind to FXIa but not to FXI, and has the effect of inhibiting the endogenous pathway of human coagulation without affecting the exogenous pathway thereof, which can significantly inhibit the formation of arteriovenous shunt thrombosis, but does not increase the bleeding time and volume. Same has the potential to become an antithrombotic drug.

Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

The present invention relates to an antibody binding to lymphocyte activation gene-3 (LAG-3) and use thereof.

Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof

Provided is a long-acting PCSK9-specific binding protein and application thereof. Provided is an MV072 protein with unique complementarity-determining regions, i.e., a binding protein specifically binding to proprotein convertase subtilisin kexin type 9 (PCSK9). The protein can specifically bind to PCSK9, effectively inhibit the function of PCSK9 and reduce plasma LDL cholesterol level. Further provided is an application of the binding protein in treating diseases related to or influenced by the function of PCSK9.

Long-acting PCSK9-specific binding protein and application thereof

The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.

Anti-angiogenesis fusion proteins

Growing community of inventors

Shanghai, China

Shaoxiong Wang